Verenium Announces $13M Debt Repurchase

Verenium Corporation VRNM, a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that it repurchased $13 million in principal amount of its 8% Notes, as well as $8 million in principal amount of $5.5% Notes. No additional 8% Notes remain outstanding after this transaction. In total, the Company has repurchased $21 million in principal amount of its 8% and 5.5% Notes, leaving an aggregate of $74.7 million in principal amount of 5.5% and 9% Notes outstanding. To effect this repurchase, the Company paid a total of $20.6 million in cash to a group of institutional investors, excluding accrued interest as of the closing date.